Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899353 · ClinicalTrials.gov registry record · Phase 2
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
A Phase 2 study, sponsored by Marshall University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00899353 is a Phase 2 study that was terminated before completion, run by Marshall University. The registered enrollment target is 16 participants.
The verdict
NCT00899353, a Phase 2 study, was terminated before completion, sponsored by Marshall University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the study is to determine if the Omega 3 supplementation will help prevent or delay progression of the disease to a stage that requires treatment.
Interventions
- DIETARY_SUPPLEMENT Omega 3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899353
The ClinicalTrials.gov registry entry for NCT00899353 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marshall University, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omega 3 Fatty Acid is the first listed.
NCT00899353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899353 about?
NCT00899353 is a clinical study titled "Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)". Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the s...
What is the current status of trial NCT00899353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00899353?
The interventions under investigation include: Omega 3 Fatty Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00899353?
This trial is sponsored by Marshall University, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.